Praxis Precision Medicines to Participate in TD Cowen’s 44th Annual Health Care Conference

Praxis Precision Medicines to Participate in TD Cowen’s 44th Annual Health Care Conference




Praxis Precision Medicines to Participate in TD Cowen’s 44th Annual Health Care Conference

BOSTON, March 01, 2024 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in the TD Cowen 44th Annual Health Care Conference, taking place in Boston from March 4 – 6, 2024. In addition to conducting one-on-one investor meetings, management will participate in a corporate panel discussion.

Panel Discussion Details
Title:   Orphan Epilepsies Corporate Panel Discussion
Date:   Wednesday, March 6, 2024
Time:   10:30 a.m. EST
Webcast Link:   Link
 

This live webcast will also be available through the Events & Presentations page of the Investors + Media section of the company’s website www.praxismedicines.com. A replay of the webcast will be available on Praxis’ website for 90 days following the event.

About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.

CONTACT: Investor Contact: 
Praxis Precision Medicines 
investors@praxismedicines.com 
857-702-9452 
 
Media Contact:
Dan Ferry
Life Science Advisors
Daniel@lifesciadvisors.com
617-430-7576